WO2014001988A3 - USE OF CTBP1 siRNA FOR THE TREATMENT OF GASTRIC CANCER - Google Patents

USE OF CTBP1 siRNA FOR THE TREATMENT OF GASTRIC CANCER Download PDF

Info

Publication number
WO2014001988A3
WO2014001988A3 PCT/IB2013/055125 IB2013055125W WO2014001988A3 WO 2014001988 A3 WO2014001988 A3 WO 2014001988A3 IB 2013055125 W IB2013055125 W IB 2013055125W WO 2014001988 A3 WO2014001988 A3 WO 2014001988A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
ctbp1
sirna
treatment
ctbp
Prior art date
Application number
PCT/IB2013/055125
Other languages
French (fr)
Other versions
WO2014001988A2 (en
Inventor
Manuel Gidekel
Carolina BIZAMA
Osvaldo Podhajcer
Original Assignee
Manuel Gidekel
Bizama Carolina
Osvaldo Podhajcer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manuel Gidekel, Bizama Carolina, Osvaldo Podhajcer filed Critical Manuel Gidekel
Publication of WO2014001988A2 publication Critical patent/WO2014001988A2/en
Publication of WO2014001988A3 publication Critical patent/WO2014001988A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention encompasses a novel composition comprising silenced CTBP- combined with a compound selected from among 5-FU, Cisplatin and Epirubicin. The invention further relates to a method of treating gastric cancer with a combination ofsi RNA silenced CTBP-1 and a compound selected from among 5-FU, Cisplatin and Epirubicin.
PCT/IB2013/055125 2012-06-25 2013-06-21 USE OF CTBP1 siRNA FOR THE TREATMENT OF GASTRIC CANCER WO2014001988A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261690392P 2012-06-25 2012-06-25
US61/690,392 2012-06-25

Publications (2)

Publication Number Publication Date
WO2014001988A2 WO2014001988A2 (en) 2014-01-03
WO2014001988A3 true WO2014001988A3 (en) 2014-11-20

Family

ID=49783955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/055125 WO2014001988A2 (en) 2012-06-25 2013-06-21 USE OF CTBP1 siRNA FOR THE TREATMENT OF GASTRIC CANCER

Country Status (1)

Country Link
WO (1) WO2014001988A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003943A1 (en) * 2004-08-09 2007-01-04 Northwestern University Tumor angiogenesis inhibitor alpha 1-antitrypsin
US20090023149A1 (en) * 2005-12-01 2009-01-22 Steen Knudsen Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20100239653A1 (en) * 2000-10-16 2010-09-23 Kotinos Pharmaceuticals Inc. Pharmaceutical preparations and methods for inhibiting tumors
US20110086349A1 (en) * 2007-10-05 2011-04-14 Ahmad Anjomshoaa Proliferation Signatures and Prognosis for Gastrointestinal Cancer
US20120156310A1 (en) * 2009-05-22 2012-06-21 Taiho Pharmaceutical Co., Ltd. Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239653A1 (en) * 2000-10-16 2010-09-23 Kotinos Pharmaceuticals Inc. Pharmaceutical preparations and methods for inhibiting tumors
US20070003943A1 (en) * 2004-08-09 2007-01-04 Northwestern University Tumor angiogenesis inhibitor alpha 1-antitrypsin
US20090023149A1 (en) * 2005-12-01 2009-01-22 Steen Knudsen Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20110086349A1 (en) * 2007-10-05 2011-04-14 Ahmad Anjomshoaa Proliferation Signatures and Prognosis for Gastrointestinal Cancer
US20120156310A1 (en) * 2009-05-22 2012-06-21 Taiho Pharmaceutical Co., Ltd. Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BELIAN ET AL.: "Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells.", ANTICANCER RES., vol. 30, no. 2, 2010, pages 629 - 33 *
BIRTS ET AL.: "Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.", BIOL CELL, vol. 103, no. 1, 2010, pages 1 - 19 *
BIZAMA ET AL.: "The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer.", INTERNATIONAL JOUMAL OF CANCER, 1 August 2013 (2013-08-01) *
CHINNADURAI.: "The transcriptional corepressor CtBP: a foe of multiple tumor suppressors.", CANCER RES., vol. 69, no. 3, 2009, pages 731 - 734 *
DENG ET AL.: "MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines.", INT J BIOL SCI., vol. 7, no. 1, 2011, pages 133 - 137 *
JIN ET AL.: "Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human . multidrug resistant cancer cells.", BIOCHEM PHARMACOL., vol. 74, no. 6, 2007, pages 851 - 859 *
STRAZA ET AL.: "Therapeutic targeting of C-terminal binding protein in human cancer.", CELL CYCLE, vol. 9, no. 18, 2010, pages 3740 - 50 *
STRAZA.: "A Tale of Two ARFs: Tumor Suppressor and Antiviral Functions of p14ARF: A Dissertation.", PHD THESIS., 21 May 2010 (2010-05-21), Retrieved from the Internet <URL:http://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1476&context=gsbs_diss&sei-redir=1&referer=http%3A%2F%2Fscholar.google.com%2Fscholar%3Fq%3Dstomach%2Bctbp%26hl%3Den%26as_sdt%3D400005%26sciodt%3D0%252C14%26cites%3D18012986155936661275%26scipsc%3D1#search=%22stomach%20ctbp%22> [retrieved on 20121205] *
WINKLMEIER ET AL.: "Loss of full length CtBP1 expression enhances the invasive potential of human melanoma.", BMC CANCER, vol. 9, 2009, pages 52 *
YUAN ET AL.: "Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].", AI ZHENG., vol. 28, no. 4, 2009, pages 337 - 43 *
ZHANG ET AL.: "Redox sensor CtBP mediates hypoxia-induced tumor cell migration.", PROC NATL ACAD SCI USA, vol. 103, 2006, pages 9029 - 33 *

Also Published As

Publication number Publication date
WO2014001988A2 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
EP2714081A4 (en) Methods, compositions, and kits for the treatment of cancer
WO2014144978A3 (en) Improved compositions for treating muscular dystrophy
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
WO2014113089A3 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
IL215682A0 (en) Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
MX2015008697A (en) Age-related macular degeneration treatment.
EP3018209A4 (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease
WO2013056148A3 (en) Scd1 antagonists for treating cancer
EP2895609A4 (en) Methods and compostions for the specific inhibition of myc by double-stranded rna
PL2922828T3 (en) 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer
WO2012118903A3 (en) Sclerostin and dkk-1 bispecific binding agents
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
WO2013173759A3 (en) Macrocyclic nucleoside phosphoramidate derivatives
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2013034989A3 (en) Microrna-based methods and assays for osteosarcoma
WO2013120022A3 (en) Treatment of hypoglycemia
WO2013023043A3 (en) Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
EP3019612A4 (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
WO2012017321A3 (en) Treatment for dyslipidemia
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
EP3019611A4 (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2012170720A3 (en) Methods and compositions for treating brain cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13809009

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13809009

Country of ref document: EP

Kind code of ref document: A2